Skip to main content


We Won't Rest

We Won't Rest

We Won't Rest

We will not rest in our mission to bring scientific breakthroughs to the people who need them most

Dr Paul Janssen once said, 'patients are waiting'. These words continue to be at the heart of everything we do. They fuel our tireless efforts to fight disease and bring meaningful solutions to patients and those who care for them.

That is why we are supporting the #WeWontRest campaign, a cross-industry campaign supported by the European Federation of Pharmaceutical Industries and Associations (EFPIA) that focuses on the importance of innovation to transform the lives of patients.

Illness never sleeps, which is why at Janssen, we're constantly working on technological breakthroughs that have the power to transform how diseases are treated.

Watch our leaders say why We Won't Rest in the fight against disease

Read more about our work

Make Blood Cancer Visible

Despite blood cancers making up 7% of all cancers worldwide, their disparate nature means they often go unseen. However, their economic impact is substantial: the total cost of blood cancers to the EU economy is €12 billion, and healthcare costs per patient are almost two times higher when compared to the average cost across all cancers. 

Awareness of blood cancers and their symptoms is low but their impact on people’s lives and the global economy is high. Through our ‘Make Blood Cancer Visible’ campaign, we are working with the global cancer community to change this and to build greater awareness of the true impact of these cancers. #WeWontRest until we can deliver solutions that make blood cancers like multiple myeloma a chronic but manageable condition.

More on Multiple myeloma

Mental health innovation is a global responsibility

Janssen has a longstanding heritage in neuroscience and continues to be a pioneer in the field; one of Dr Paul Janssen’s first medical breakthroughs was the development of a medicine for people suffering from schizophrenia that allowed them to be treated without the need for institutionalisation.

Our understanding of psychiatric conditions and neurodegenerative diseases has evolved at a tremendous rate since the 1950s. But, although our scientific knowledge in this field has increased, so has the number of people affected by mental health issues – for example, it is estimated that in Europe, schizophrenia affects 3.7 million people and more than 40 million people are now living with depression.

Mental health conditions are associated with considerable disability and high economic and social costs – in Europe, up to a third of the population live with mental health problems. In 2015, the number of in-patient bed days for mental and behavioural disorders in the EU was more than 83 million – second only to diseases of the circulatory system. 

We are all united in our mission to deliver innovative, differentiated medicines that address the most serious unmet medical needs. Disease does not rest, and that is why we will not rest while patients are still waiting. #WeWontRest

More on Neuroscience

Precision medicine can revolutionise healthcare

Precision medicine has the potential to turn science fiction into reality. This approach could deliver significant societal value and reduce the burden of disease by detecting, preventing, and treating some of the most complex diseases, such as cancer.

We are proud of our partnerships and our groundbreaking collaborations that constantly push the boundaries of science in order to develop the next generation of personalised medicines and drive progress in cancer care. But while innovative treatments are powerful tools in treating potentially deadly diseases, we can only realise the full potential of medical breakthroughs if we maintain an environment where innovation can thrive.

#WeWontRest until we find a cure for each and every type of cancer.

More on Oncology